Lymphokine-activated killer cell
In
Mechanism
It has been shown that
The mechanism of LAK cells is distinctive from that of
Cancer Treatment
LAK cells, along with the administration of IL-2 have been experimentally used to treat cancer in mice and humans, but there is very high toxicity with this treatment - Severe fluid retention was the major side effect of therapy, although all side effects resolved after interleukin-2 administration was stopped.[5] LAK cell therapy is a method that uses interleukin 2 (IL-2) to enhance the number of lymphocytes in an in vitro setting, and it has formed the foundation of many immunotherapy assays that are now in use.[6] LAK cells have shown potential as a cellular agent for cancer therapy and have been utilized therapeutically in association with IL-2 for the treatment of various cancers. LAK cells have anticancer efficacy against homologous carcinoma cells and can grow ex vivo in the presence of IL-2.[7] In melanoma and gastric cancer cells, intercellular adhesion molecule 1 (ICAM-1) antibody can significantly inhibit in vitro LAK-induced lysis of cancer cells. A study has shown that ICAM1 in lung cancer cells increases LAK cell-mediated tumor cell death as a new anti-tumor mechanism.[8]
Notes and references
- ^ "Definition of lymphokine-activated killer cell". National Cancer Institute. Retrieved 2007-03-06.
- ^ "Medical Dictionary: Lymphokine-activated killer cell". Wrong Diagnosis. Retrieved 2007-03-06.
- PMID 3549471.
- ^ PMID 3893689.
- PMID 3903508.
- PMID 31360654.
- PMID 23982804.
- PMID 25069049.
External links
- Lymphokine-Activated+Killer+Cells at the U.S. National Library of Medicine Medical Subject Headings (MeSH)